Project information

Fund research for Acute Leukaemia in children

Leuka is UK’s leading leukaemia research charity that funds research to bring new treatments and cures to patients as quickly as possible. By giving access to the latest clinical trials we are saving lives.

3 years

Charity information: Leuka

Leuka logo
  • Need

    Need

    Leukaemia is the most common form of childhood cancer and new treatments are urgently needed. That’s why Leuka’s researchers are working to help infants with a rare form of acute leukaemia, Mixed Lineage Leukaemia (MLL), that has very poor outcomes. Our specialist doctors and scientists are focussed on developing treatments that will target the mutated protein that causes MLL and that is currently “undruggable”. At present there are no effective treatments available for devastating disease.

    Solution

    Leuka’s researchers are working hard to discover new treatments with better outcomes. They are focused on both improving the effectiveness of treatments (to cure more patients) and reducing the side effects (to give a better quality of life after leukaemia treatments). They believe their work on Mixed Lineage Leukaemia (MLL) could be a game changer in the treatment of this awful childhood cancer.

  • Aims

    Aim 1

    Therapeutic Targeting of MLL-fusion Degradation in Acute Myeloid Leukaemia


    Activities

    » Fund this specific research and help this team to investigate what impact this targeted treatment could have, using pre-clinical models.

    What success will look like

    When this study is complete, the research into this treatment could potentially progress to clinical trials to start saving young lives.


  • Impact

    Impact

    Similar treatments for other leukaemias have been discovered with dramatic results. We hope that by the end of Leuka’s grant, the research team will be ready to initiate clinical trials that may ultimately help infant patients with this horrible disease. In Dr de Boer’s words: “Everybody who donates makes a really big contribution and we can get a new drug into the clinic and give hope to patients, including infants, with MLL, who currently have little hope.”

    Risk

    The scientific experiment fails to get the right result. More research will be needed and further funding will need to be found. The research could also take longer than expected, but careful monitoring throughout the project should help mitigate this risk.

    Reporting

    We will report about this project to our donors through our annual reports, newsletters and social media. We also ask that the researchers publish their research findings in accordance with the terms and conditions of accepting the funding.

  • Budget

    Budget - Project Cost: £247,000

    Loading graph....
      Amount Heading Description
      £171,500 Salaries costs of employing researchers
      £35,000 Laboratory costs consumables
      £40,500 Experiments Analysis and pre-clinical tests
  • Background

    Location

    UCL Great Ormond Street Institute of Child Health

    Beneficiaries

    Infants with Acute Leukaemia and all patients with Mixed Lineage leukaemia (MLL).

  • Why Us?

    Why Us?

    As the leading leukaemia research charity, we are determined to improve the understanding of leukaemia, find new treatments as soon as possible and ultimately a cure. We are committed to funding only the very best research and exceptional scientists.

    Read more about the Charity running this project.

    People

    Dr Dawn Farrar

    Dr Farrar is our Research Development Manager who reviews applications and forwards them for Peer Review by Leuka’s Independent Scientific Panel.